

Test with precision, treat with confidence.


Drug Response Testing for Acute Myeloid Leukemia

Find the right treatment
for your AML patient –
at every stage of the
journey

PrevisionOne™, our ex vivo drug response testing platform, helps support treatment strategy in AML by testing drug responses directly on primary **patient samples**. Powered by our **Previ384™** software, PrevisionOne™ can evaluate over 100 therapies across **three specialized AML panels** for early, relapsed, and refractory AML profiles. In just **three working days**, we deliver a **personalized drug response report** to support healthcare professionals to guide personalized treatment options.

Why choose PrevisionOne™?

- ✓ **Proven Survival Benefit: 3.4x higher Overall Survival** in patients with R/R AML versus standard guidelines.
- ✓ **100+ Therapies Across 3 Specialized Panels:** Select the panels most relevant to your patient.
- ✓ **Cancer-Specific Drug Ranking:** Drugs are ranked by weighing **cancer cell** vs. **healthy cell** killing.
- ✓ **Rapid Turnaround:** Receive drug response reports in just **3 working days** from sample delivery.



Behind PrevisionOne™ and Previ384™

Award-winning technology

Pharmacoscopy

The clinically most validated functional precision medicine method to date

- Studies published in Cancer Discovery, Hematologica, Blood Cancer Discovery.
- Developed in collaboration with Med Uni Wien, Inselspital Bern and Universitätsspital Basel.
- Adopted by leading European university hospitals, including Universitätsspital Zurich, Inselspital Bern and Universitätsspital Basel.



CANCER DISCOVERY



haematologica

BLOOD CANCER DISCOVERY

Available as a **Research Use Only** service supporting hematologists in personalized treatment selection by testing drug responses directly on primary patient samples.

Get in touch with us to learn more.

Prevision Medicine AG
Zurich, Switzerland
www.previsionmedicine.com



Prevision Medicine



info@previsionmedicine.com

Spin-off | **ETH** zürich